



<input type="checkbox"/>	Trading – Interest Rate Derivatives	<input checked="" type="checkbox"/>	Back-office - Options
<input checked="" type="checkbox"/>	Trading – Equity and Index Derivatives	<input checked="" type="checkbox"/>	Technology
<input type="checkbox"/>	Back-office – Futures	<input checked="" type="checkbox"/>	Regulation

CIRCULAR
May 2, 2013

ANTICIPATED CONTRACT ADJUSTMENT
Resverlogix Corp. (RVX)
Spin-Off

THE FOLLOWING INFORMATION IS PREPARED FOR THE CONVENIENCE OF CANADIAN DERIVATIVES CLEARING CORPORATION (CDCC) MEMBERS AND BOURSE DE MONTRÉAL INC. (THE BOURSE) APPROVED PARTICIPANTS. THIS DOCUMENT IS AN UNOFFICIAL SUMMARY OF CERTAIN TERMS OF THE AFOREMENTIONED ADJUSTMENT. CDCC AND THE BOURSE ACCEPT NO RESPONSIBILITY FOR THE ACCURACY OR COMPLETENESS OF THE SUMMARY. CDCC MEMBERS AND BOURSE APPROVED PARTICIPANTS MUST ENSURE THEY HAVE REVIEWED THE DOCUMENTATION PUBLISHED BY THE ISSUERS INVOLVED IN THIS CORPORATE ACTION.

The Bourse and CDCC wish to inform you that Resverlogix Corp. (“Resverlogix”) announced on May 1, 2013, that its Board of Directors has approved the Plan of Arrangement (“the Arrangement”) to spin-off its subsidiary RVX Therapeutics Inc. (“RVX Therapeutics”). Resverlogix has entered into an Arrangement Agreement with RVX Therapeutics and a newly-incorporated company (“Spinco”), which provides for the acquisition of RVX Therapeutics by Spinco. The spin-off will be transacted by the way of a distribution, pursuant to which each Resverlogix shareholder will receive one common share of Spinco for each common share of Resverlogix held immediately prior to the arrangement becoming effective. It is anticipated that Resverlogix shares will commence trading on a “due bill” basis on or about June 3, 2013.

Spinco shares will not be listed on any stock exchange at this time and this decision will be reconsidered in the future by Spinco Board.

The plan of arrangement is subject to the approval of 66 2/3 % of Resverlogix shareholders whose votes will be cast at a special meeting expected to be held on May 28, 2013. The transaction is also subject to all the necessary regulatory approvals.

PLEASE ENSURE THAT ALL CLIENTS WHO HAVE EITHER LONG OR SHORT POSITIONS IN THIS OPTION CLASS ARE ADVISED OF THIS NOTICE.

For further information, please contact Louise Leclair, Trading Systems Analyst Market Operations, Bourse de Montréal Inc. at (514) 871-3526. CDCC clearing members may contact the Member Services Department.

Brian Gelfand
 Vice-President, Institutional Relations and Market Operations

Circular no.: 084-2013